These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2938737)

  • 1. Analysis of the cellular immune response to and adoptive immunotherapy of a BALB/c lymphoma that cross-reacts with normal DBA/2 cells.
    Sensi M; Grazioli L; Parmiani G
    Cancer Immunol Immunother; 1986; 21(3):199-204. PubMed ID: 2938737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adoptive immunotherapy of a BALB/c lymphoma by syngeneic anti-DBA/2 immune lymphoid cells: characterization of the effector population and evidence for the role of the host's non-T cells.
    Colombo MP; Parenza M; Parmiani G
    Cancer Immunol Immunother; 1985; 20(3):198-204. PubMed ID: 3851699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
    Sensi ML; Parenza M; Parmiani G
    J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive adoptive immunotherapy of low-immunogenic BALB/c lymphoma by syngeneic alloimmune T lymphocytes.
    Colombo MP; Arioli I; Parmiani G
    Int J Cancer; 1984 Dec; 34(6):807-13. PubMed ID: 6334656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DBA/2-like minor histocompatibility antigens on a BALB/c lymphoma. A BALB/c anti-DBA/2 serum which lyses the tumor and blocks BALB/c anti-tumor and anti-DBA/2 effectors.
    Ballinari D; Grazioli L; Sensi ML; Borrello MG; Parmiani G
    Int J Cancer; 1985 Nov; 36(5):617-22. PubMed ID: 3877002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactions between tumor cells and allogeneic normal tissues. Inhibition of a syngeneic lymphoma outgrowth in H-2 and non-H-2 alloimmune BALB/c mice.
    Parmiani G; Sensi ML; Carbone G; Colombo M; Pierotti M; Ballinari D; Hilgers J; Hilkens J
    Int J Cancer; 1982 Mar; 29(3):323-32. PubMed ID: 7068280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential resistance to growth of a tumor expressing incompatible minor alloantigens reflects regulatory influences rather than differences in anti-minor-CTL-P frequencies.
    Carayanniotis G; Halloran PF
    Cell Immunol; 1985 Mar; 91(1):100-10. PubMed ID: 2857596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of a disseminated mouse lymphoma by 1,3-bis(2-chloroethyl)-1-nitrosourea is immunologically mediated and accompanied by de novo generation of anti-tumor cytotoxicity.
    Sensi M; Bergomi M; Formelli F; Parmiani G
    Int J Cancer; 1990 Dec; 46(6):1088-94. PubMed ID: 2249896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conditioning of the secondary cytotoxic T-lymphocyte response to YC8 tumor.
    Ghanta VK; Hiramoto NS; Soong SJ; Hiramoto RN
    Pharmacol Biochem Behav; 1995 Mar; 50(3):399-403. PubMed ID: 7617678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of non-H-2 genes in the control of the in vivo growth of the virus induced lymphoma YC8.
    Colombo MP; Parmiani G
    J Immunogenet; 1981 Oct; 8(5):405-13. PubMed ID: 6795282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma.
    Grazioli L; Sensi M; Parmiani G
    Cancer Immunol Immunother; 1987; 24(3):237-43. PubMed ID: 2954636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the YC8 lymphoma growth by alloimmunization with normal cells.
    Parmiani G; Sensi ML
    Transplant Proc; 1981 Dec; 13(4):1906-9. PubMed ID: 7330975
    [No Abstract]   [Full Text] [Related]  

  • 14. Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden.
    Formelli F; Rossi C; Sensi ML; Parmiani G
    Int J Cancer; 1988 Dec; 42(6):952-7. PubMed ID: 3263956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.
    Hines DL
    Cancer Immunol Immunother; 1989; 28(4):241-7. PubMed ID: 2495177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of an allogeneic antigen to induce resistance and regression of an autologous tumor.
    Hiramoto RN; Ghanta VK; Soong SJ; Hiramoto NS
    J Immunother Emphasis Tumor Immunol; 1994 Apr; 15(3):202-11. PubMed ID: 8032543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic effects of antigen- and mitogen-induced T cells on various targets.
    Bevan MJ; Cohn M
    J Immunol; 1975 Feb; 114(2 Pt 1):559-65. PubMed ID: 123541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction and characterization of minor histocompatibility antigens. Specific primary cytotoxic T lymphocyte responses in vitro.
    Ando K; Nakashima I; Nagase F; Isobe K; Kawashima K; Hasegawa Y; Yoshida T; Iwamoto T; Hasegawa T; Muro Y
    J Immunol; 1988 Feb; 140(3):723-9. PubMed ID: 2448374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immune cells in the Pavlovian conditioning of specific resistance to cancer.
    Hiramoto RN; Hiramoto NS; Rish ME; Soong SJ; Miller DM; Ghanta VK
    Int J Neurosci; 1991 Jul; 59(1-3):101-17. PubMed ID: 1774131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor-protectivity of cytotoxic donor cells.
    Zangemeister-Wittke U; Schirrmacher V
    Biotherapy; 1991; 3(4):319-29. PubMed ID: 1786195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.